Find and Pitch Jounalists, Get Your Story Covered

Tags: Pharmaceuticals STAT+pharmalittle | STAT+pharmalittle drug development | Drug prices | drug pricing | Pharmaceuticals | pharmalittle | research

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 3 days ago STAT+: Up and down the ladder: The latest comings and goings - 6 days ago STAT+: Pharmalittle: We’re reading about FDA plans to ban a cold med; Eisai Alzheimer’s drug sales, and more - 6 days ago STAT+: Pharmalittle: We’re reading about compounded Wegovy, pharmacies suing GoodRx, and more - 8 days ago STAT+: Pharmalittle: We’re reading about Medicaid coverage of obesity drugs, a death in a sickle cell trial, and more - 9 days ago STAT+: Pharmalittle: We’re reading about a weight loss pill, the FDA warning a compounder, and more - 10 days ago STAT+: Up and down the ladder: The latest comings and goings - 13 days ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 14 days ago STAT+: Two generic drugmakers to pay $49 million to settle price-fixing charges - 14 days ago STAT+: Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more - 18 days ago STAT+: Up and down the ladder: The latest comings and goings - 20 days ago STAT+: Pharmalittle: We’re reading about FDA oversight of shortages, AstraZeneca threats, and more - 21 days ago STAT+: Pharmalittle: We’re reading about drug shortages, what drugmakers didn’t tell Alzheimer’s trial patients and more - 22 days ago STAT+: Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more - 25 days ago STAT+: Sales from controversial drug discount program rose to $63 billion last year - 27 days ago STAT+: Up and down the ladder: The latest comings and goings - 27 days ago STAT+: Pharmalittle: We’re reading about a new CVS chief, obesity meds cutting overdoses, and more - 28 days ago STAT+: Pharmalittle: We’re reading about doctors powering telehealth GLP-1 scripts, an FDA hold on a Novavax shot, and more - 29 days ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 2 months ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 2 months ago STAT+: Pharmalittle: We’re reading about China detaining AstraZeneca staff, pharma layoffs, and more - 2 months ago STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about AstraZeneca threatening the U.K., mpox vaccine distribution, and more - 3 months ago STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - 3 months ago STAT+: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about a Covid-flu shot setback, mpox vaccine supplies, and more - 3 months ago STAT+: Pharmalittle: We’re reading about FDA rejecting MDMA; a nasal spray for allergic reactions, and more - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about a California bill to restrain PBMs, a U.K. trade group scolding Novo, and more - 3 months ago STAT+: Pharmalittle: We’re reading about a CVS deal with Illinois, a Pfizer hemophilia therapy, and more - 4 months ago STAT+: Pharmalittle: We’re reading about PBM practices, DOJ tussling with Regeneron, and more - 4 months ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 4 months ago STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Pharmalittle: We’re reading about a study of Ozempic and dementia, smaller PBMs, and more - 4 months ago STAT+: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more - 4 months ago STAT+: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes - 4 months ago STAT+: Pharmalittle: We’re reading about Ozempic and an eye condition, a failed Roche cancer drug trial, and more - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Pharmalittle: We’re reading about the Purdue bankruptcy ruling, a Merck rejection, and more - 5 months ago STAT+: Pharmalittle: We’re reading about a Merck pneumococcal shot, Kansas suing Pfizer, and more - 5 months ago STAT+: Pharmalittle: We’re reading about Sanders dogging Novo Nordisk, Teva patents, and more - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Pharmalittle: We’re reading about drug shortages, Medicare spending on an Alzheimer’s drug, and more - 7 months ago STAT+: European Parliament votes in favor of updated pharma legislation, prompting mixed reactions - 7 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 7 months ago STAT+: FDA agrees to review a rare disease drug that its developer was about to give up on - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 7 months ago STAT+: Pharmalittle: We’re reading about a White House drug-shortage plan, a Genmab deal, and more - 8 months ago STAT+: Pharmalittle: We’re reading about a European probe into vaccine talks; net drug prices falling, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Wegovy insurance coverage, Zepbound shortages, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 8 months ago STAT+: Pharmalittle: We’re reading about a Novo Nordisk deal, a Regeneron setback, and more - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, FDA syringe warnings, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, GSK asthma inhalers, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Europe’s pharma reform, weight-loss meds, and more - 8 months ago STAT+: Pharmalittle: We’re reading about an AstraZeneca deal, a WHO pandemic pact, and more - 8 months ago STAT+: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more - 9 months ago STAT+: Pharmalittle: We’re reading about state moves on drug pricing, an asthma med for kids and more - 9 months ago STAT+: Pharmalittle: We’re reading about a U.S. vaccine panel, an abortion pill, and much more - 9 months ago STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more - 10 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 10 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - 11 months ago STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles - 11 months ago STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access - 11 months ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - 11 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 11 months ago STAT+: Pharmalittle: U.S. Senate eyes more policies for regulating PBMs; Novo claims most U.S. Wegovy patients pay less than $25 a month - about 1 year ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - about 1 year ago STAT+: Pharmalittle: Pharma likely to expand legal attacks on Medicare negotiations; CDC recommends rationing RSV drug - about 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - about 1 year ago STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties - about 1 year ago
2	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Pharmalittle: We’re reading about an Italian acquisition, Medicare Advantage market growth, and more - about 1 month ago STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal - 2 months ago STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more - 3 months ago STAT+: Pharmalittle: We’re watching more positive data for Ozempic, a Lilly factory expansion, and more - 6 months ago
3	Bob Herman STAT News Health care business reporter. Indiana Health carebusiness	STAT+: Medicare Advantage market expected to grow in 2025, despite big changes from insurers - about 1 month ago
4	Tara Bannow STAT News Reporter @statnews. healthcarejournalism	STAT+: Medicare Advantage market expected to grow in 2025, despite big changes from insurers - about 1 month ago
5	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: A new drug offers a rare option for brain cancer treatment — and inspires hopes for more - 2 months ago STAT+: Pharmalittle: We’re watching positive Zepbound cardiovascular data, a move to take 23andMe private, and more - 4 months ago STAT+: Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried - 5 months ago
6	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: A rare disease program, portrayed as both lifeline and pharma handout, is set to expire - 2 months ago
7	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: A rare disease program, portrayed as both lifeline and pharma handout, is set to expire - 2 months ago
8	Mario Aguilar STAT News Reporter at STATnews. Previous engagements noted. Personal views. Brooklyn techhealth care	STAT+: Why clinical trials for digital therapeutics are getting more rigorous - 4 months ago STAT+: Better Therapeutics data on apps’ benefit with GLP-1s, Orexo hits a snag - about 1 year ago
9	PT Staff Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Condition Watch, June 2024 - 5 months ago Condition State Management: Stroke Watch - about 1 year ago
10	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical - 6 months ago

Journalists covering pharmalittle | STAT+